Guangzhou Innogen Pharmaceutical Group Co., Ltd (2591.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$3.24 (-1.52%) as of
Key statistics
- Market cap
- 1.48B
- Forward P/E
- -21.97
- EPS (TTM)
- -0.870
- Dividend yield
- 0.00%
- 52-week range
- 3.130 – 48.360
- Revenue (TTM)
- 153.28M
- Profit margin
- -218.13%
- Analyst target
- HK$20.67
- Volume
- 3.12M
About Guangzhou Innogen Pharmaceutical Group Co., Ltd
Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company's products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Shanghai, China
- Employees
- 214
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.